XLA-associated neutropenia treatment: a case report and review of the literature.
X-linked agammaglobulinemia (XLA) is a primary B-cell deficiency syndrome with an incidence of 5 to 10 cases per million. The current treatment approach includes intravenous immunoglobulin and aggressive antibiotic regimens for infections. Besides recurrent infections, XLA patients may present with other manifestations, such as alopecia, enteropathy, amyloidosis, and neutropenia. Neutropenia, which has been shown in up to 25% of affected patients, might also contribute to the degree of severity of bacterial infections that have been reported in these cases. Here we present our experience with the granulocyte colony-stimulant factor, filgrastim (Neupogen), in the treatment of neutropenia in a 14-month-old child with XLA.
Jacobs
Zachary David
ZD
Department of Child Health, J. Otto Lottes Health Sciences Library, University of Missouri-Columbia, Columbia, MO 65212, USA.
Guajardo
Jesus Ramon
JR
Anderson
Katherine Marie
KM
D000361:Agammaglobulinemia / Q000150:complications* / Q000503:physiopathology; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000069585:Filgrastim; D040181:Genetic Diseases, X-Linked / Q000150:complications* / Q000503:physiopathology; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007223:Infant; D041121:Klebsiella oxytoca; D007711:Klebsiella pneumoniae; D009503:Neutropenia / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D011018:Pneumonia, Pneumococcal; D011994:Recombinant Proteins; D013296:Streptococcus pneumoniae
D000900:Anti-Bacterial Agents; D016756:Immunoglobulins, Intravenous; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim